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We would like to emphasize the importance of actively
searching for infections, even if not clinically evident, in any
cirrhotic patient with cognitive impairment.
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cirrhotic, more Child-Pugh B patients were in the TACE group
(although this approached, but did not reach statistical signiﬁ-
cance). Finally, the authors highlight the poorer than anticipated
outcomes from TACE and the lack of access to drug eluted beads
[3–6]. The lack of access to these treatments is understandable,
but the questions remain: ‘‘Would the outcomes have been dif-
ferent had this been available’’? In summary, the fact that Yin
and colleagues were able to perform and complete this study is
a major achievement, but due to the understandable difﬁculties
in the methodology, it would be too early to suggest that BCLC
B patients outside Milan should be offered surgery before TACE.
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Yin and colleagues are to be congratulated on having performed
an RCT in such a challenging study population [1]. The results are
strongly supportive of surgery in preference to transarterial
chemoembolization (TACE), in patients beyond Milan criteria at
BCLC B. But, the ﬁndings must be viewed with caution before a
similar approach is pursued in different patient populations.
Firstly, the disease aetiology was almost exclusively due to
chronic hepatitis B infection. A recent UK study showed that
70% of cases of HCC were due to alcoholic liver disease, fatty liver
disease, and cryptogenic disease, so the patient groups between
geographical locations are clearly very different and thus not
comparable. Furthermore, the mean age in the far eastern popu-
lation was 52 and 54 years for the partial hepatectomy patients
and TACE patients, respectively. This compares with a median
age of 69.9 years in the study from the Newcastle group [2].
Excluding patients 70 years or older is likely to have introduced
a selection bias to the study, since older patients are more likely
to have signiﬁcant co-morbidities that would preclude major
liver resection. The normal platelet counts may also hint at low
levels of signiﬁcant portal hypertension, which is known to be
associated with poorer outcomes following partial hepatectomy.
Moreover, 22% of the surgical patients and 13% of the TACE
patients were not cirrhotic, but for those patients who wereJournal of Hepatology 2015 vol. 62 j 739–752 747
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To the Editor:
We read with interest the article by Yin et al. [1], in which they
highlighted that partial hepatectomy (PH) was superior to
transcatheter arterial chemoembolization (TACE) for patients
with resectable multiple hepatocellular carcinoma (HCC) beyond
the Milan criteria. However, their ﬁndings may need further
improvement based on the following two viewpoints.
First, the authors excluded patients whose platelet count (PLT)
was <80  109/L, which might be in view of the inﬂuence of
thrombocytopenia on therapy. In addition, enrolled patients in
the TACE group had a lower preoperative PLT compared to
patients who received PH (Yin et al., Table 1, 154.7  109/L vs.
172.3  109/L, p = 0.087 <0.10). Therefore, we speculated that
the PLT might be a potential confounder in the association
between the type of treatment and survival in HCC, while the
authors might ignore to correct it in the multivariate analysis.
Second, the authors did not compare recurrence-free survival
(RFS) between the two groups though they considered this as a
secondary outcome measure (ClinicalTrials.gov NCT00820157).
The discordance between the publication and the registration
information might decrease the validity of their ﬁndings [2].
Whether or not the high recurrence rate (68.9%) after PH affected
RFS was not reported by Yin et al.
To estimate the signiﬁcance of PLT in the prognosis of HCC, we
retrospectively analysed in our centre 213 patients (from April
2002 until August 2012) that were beyond the Milan criteria.
91 patients received PH and 122 individuals underwent TACE.
The outcomes analysed included overall survival (OS), RFS, and
recurrence. The receiver operating characteristic curve showed
an optimal cut-off value of 156  109/L for PLT with regard to
mortality. By Log-rank test, we found that the PLT was
signiﬁcantly associated with OS and recurrence. Variables with
a p value <0.10 in the univariate analysis were entered into the
Cox proportional hazard model, and the results are presented in
Fig. 1. Out of the variables, TACE therapy, older age, and PLT
>156  109/L were independently associated with poor OS in
HCC beyond the Milan criteria. In contrast, age, PLT, and vascular
invasion, but not the type of therapy, were independent indica-
tors to predict RFS. The signiﬁcant risk factors for recurrence
included therapeutic method, gamma-glutamyltransferase
(GGT), and PLT.
Thus, we suggest that patients with a high preoperative PLT
had a signiﬁcantly worse OS and RFS, as well as a higher risk of
recurrence compared to patients with a PLT 6156  109/L, which
is consistent with previous studies [3,4]. These ﬁndings support
the hypothesis that PLT could be a confounder and should be
adjusted when estimating the independent signiﬁcance of the
type of treatment or other factors. Not only was PLT a valuable,
readily available, and inexpensive parameter to predict survival
in HCC, but it was also associated with cirrhosis formation [5]
and hepatic carcinogenesis [6]. In addition, administration of
anti-platelet agents (aspirin and clopidogrel) could prevent
hepatocarcinogenesis and greatly improve OS [7].
However, no statistically signiﬁcant difference in the RFS
between PH and TACE was observed in our study (p = 0.840).
Further studies on larger cohorts are needed to validate this
ﬁnding.
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